ENGENE HOLDINGS INC (ENGN)

CA29286M1059 - Common Stock

8.52  -0.37 (-4.16%)

After market: 8.52 0 (0%)

Fundamental Rating

2

Taking everything into account, ENGN scores 2 out of 10 in our fundamental rating. ENGN was compared to 564 industry peers in the Biotechnology industry. The financial health of ENGN is average, but there are quite some concerns on its profitability. ENGN has a expensive valuation and it also scores bad on growth.



2

1. Profitability

1.1 Basic Checks

ENGN had negative earnings in the past year.
In the past year ENGN has reported a negative cash flow from operations.

1.2 Ratios

With an excellent Return On Assets value of -14.70%, ENGN belongs to the best of the industry, outperforming 84.31% of the companies in the same industry.
With an excellent Return On Equity value of -17.03%, ENGN belongs to the best of the industry, outperforming 88.24% of the companies in the same industry.
Industry RankSector Rank
ROA -14.7%
ROE -17.03%
ROIC N/A
ROA(3y)-49.41%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ENGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, ENGN has about the same amount of shares outstanding.
ENGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 5.76 indicates that ENGN is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.76, ENGN is doing good in the industry, outperforming 79.50% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that ENGN is not too dependend on debt financing.
ENGN has a worse Debt to Equity ratio (0.09) than 63.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 5.76
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 19.52 indicates that ENGN has no problem at all paying its short term obligations.
With an excellent Current ratio value of 19.52, ENGN belongs to the best of the industry, outperforming 93.58% of the companies in the same industry.
A Quick Ratio of 19.52 indicates that ENGN has no problem at all paying its short term obligations.
ENGN has a Quick ratio of 19.52. This is amongst the best in the industry. ENGN outperforms 93.58% of its industry peers.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52

0

3. Growth

3.1 Past

The earnings per share for ENGN have decreased strongly by -263.86% in the last year.
EPS 1Y (TTM)-263.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.99%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ENGN. In the last year negative earnings were reported.
Also next year ENGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for ENGN!.
Industry RankSector Rank
Dividend Yield N/A

ENGENE HOLDINGS INC

NASDAQ:ENGN (11/4/2024, 8:05:23 PM)

After market: 8.52 0 (0%)

8.52

-0.37 (-4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap376.75M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.7%
ROE -17.03%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 19.52
Quick Ratio 19.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-263.86%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y